Equifax Inc. logo

Equifax Inc. (EFX)

Market Open
15 Jun, 16:11
NYSE NYSE
$
167. 78
+4.07
+2.4861%
$
20.31B Market Cap
57.83 P/E Ratio
2.24% Div Yield
376,218 Volume
6.64 Eps
$ 163.71
Previous Close
Add Transaction
Day Range
164.14 168.3
Year Range
153.91 275.91
Want to track EFX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Equifax Q1 Preview: Management's Thoughts On Outlook Should Be Interesting

Equifax Q1 Preview: Management's Thoughts On Outlook Should Be Interesting

Analysts expect Equifax Inc.'s Q1 '25 results to show minimal growth, with EPS estimates at $1.41 adjusted and $1.00 GAAP on $1.42B revenue. Key concerns include weak U.S. mortgage and hiring markets, with 16 downward EPS revisions adding uncertainty to the upcoming results. Focus areas include U.S. mortgage inquiry declines, Workforce Solutions headwinds, and international performance, particularly in Brazil and Europe.

Seekingalpha | 1 year ago
Here's Why Investors Must Hold Equifax Stock in Their Portfolios Now

Here's Why Investors Must Hold Equifax Stock in Their Portfolios Now

The EFX stock is gaining from its ability to sustain top-line growth momentum, fueled by synergies from buyouts and product innovation.

Zacks | 1 year ago
III vs. EFX: Which Stock Is the Better Value Option?

III vs. EFX: Which Stock Is the Better Value Option?

Investors with an interest in Consulting Services stocks have likely encountered both Information Services Group (III) and Equifax (EFX). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 1 year ago
Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across different MASH stages, positioning it uniquely against competitors like Resmetirom, which only targets F2 and F3 MASH. Akero's financial health is strong, with a cash runway until 2028, bolstered by a recent $350 million upsized offering.

Seekingalpha | 1 year ago
Bear Of The Day: Equifax (EFX)

Bear Of The Day: Equifax (EFX)

Despite beating the number in each of the last four quarters, estimates have fallen along with the Zacks Rank for this stock.

Zacks | 1 year ago
4 Undervalued Growth Stocks to Buy and Hold for the Long Term

4 Undervalued Growth Stocks to Buy and Hold for the Long Term

While most investors favor bull markets, bear markets offer unique opportunities to buy strong companies at lower prices. As the Nasdaq pulled back on Tuesday, analysts evaluated tech stocks for buying opportunities and identified potential long-term investments.

Marketbeat | 1 year ago
International Markets and Equifax (EFX): A Deep Dive for Investors

International Markets and Equifax (EFX): A Deep Dive for Investors

Evaluate Equifax's (EFX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks | 1 year ago
Equifax: Near-Term Weakness That May Lead To Guidance Revision (Rating Downgrade)

Equifax: Near-Term Weakness That May Lead To Guidance Revision (Rating Downgrade)

I am downgrading Equifax stock to a hold rating due to weak FY25 guidance, soft mortgage inquiry outlook, and hiring market pressures. Despite solid 4Q24 results and medium-term growth potential, the near-term earnings outlook is poor with decelerating revenue and EPS growth. Elevated mortgage rates and declining hiring volumes are significant headwinds, limiting EFX's ability to sustain recent growth rates.

Seekingalpha | 1 year ago
Equifax Inc. (EFX) Q4 2024 Earnings Call Transcript

Equifax Inc. (EFX) Q4 2024 Earnings Call Transcript

Equifax Inc. (NYSE:EFX ) Q4 2024 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Trevor Burns - Senior Vice President, Head of Corporate Investor Relations Mark Begor - Chief Executive Officer John Gamble - Chief Financial Officer Conference Call Participants Jeff Muller - Baird Manav Patnaik - Barclays Andrew Steinerman - JPMorgan Toni Kaplan - Morgan Stanley Faiza Alwy - Deutsche Bank Kyle Peterson - Needham Craig Huber - Huber Research Partners Jason Haas - Wells Fargo Owen Lau - Oppenheimer Andrew Nicholas - William Blair Kelsey Zhu - Autonomous Research Scott Wurtzel - Wolfe Research Matt O'Neill - FT Partners Simon Clinch - Redburn Atlantic Arthur Truslove - Citi George Tong - Goldman Sachs Operator Greetings and welcome to the Equifax Corporate's Fourth Quarter 2024 Earning Conference Call. This time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
Equifax Q4 Earnings Beat, Revenues Miss Despite Strong Segments

Equifax Q4 Earnings Beat, Revenues Miss Despite Strong Segments

Robust growth across segments drives EFX's top line in the fourth quarter of 2024.

Zacks | 1 year ago
Weaker Hiring Market Creates Revenue Headwinds for Equifax

Weaker Hiring Market Creates Revenue Headwinds for Equifax

For Equifax, macro headwinds from a job market slowdown and the volatile mortgage market — where uneven loan demand has been a hallmark amid relatively high interest rates — have impacted top-line momentum and forward-looking guidance. As discussed during an earnings call with analysts Thursday (Feb.

Pymnts | 1 year ago
Equifax (EFX) Reports Q4 Earnings: What Key Metrics Have to Say

Equifax (EFX) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Equifax (EFX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
Loading...
Load More